3 combination DM drug is cheaper than the 2 combi
By Lee, Tak-Sun | translator Kim, Jung-Ju
23.04.07 05:50:45
가나다라
0
Concern over uniformity of prescription
If meeting is included, the benefit is lower than the existing DPP4i+SGLT2i
For DPP4i+SGLT2i, all Pt copayments remain the same

2-drug combination therapy should also be provided with reimbursement standards
From this month, as it is applied to the three-drug combination therapy of SGLT2 inhibitors, prescriptions for the existing two-drug therapy (SGLT2i + DPP4i) are expected to decrease significantly.
The HIRA said on the 5th through a Q&A related to the reimbursement standards for diabetes medications that will change from this month, “The two-drug combination therapy of a combination of a DPP-4 inhibitor and an SGLT-2 inhibitor is only one type of combination within the scope of approval, as is the case at present. You can apply it with a burden,” he explained. DPP4i+SGLT2i that are currently within the scope of app
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)